Radnostix Recalls SODIUM IODIDE I-131 Capsule Kits Due to Failed Specifications, Impacting US Supply
Radnostix, Inc. has initiated a Class III voluntary recall (D-0401-2026) for 2,699 blister cartons of its Gelatin Capsule Pack, intended for use with the SODIUM IODIDE I-131 Kit, due to failed tablet/capsule specifications. This nationwide recall from their Idaho Falls, ID facility underscores critical quality control challenges for ancillary drug components, impacting supply chain reliability.
Radnostix Initiates Nationwide Recall for SODIUM IODIDE I-131 Capsule Kits Over Quality Failures
Radnostix, Inc., based in Idaho Falls, ID, has commenced a voluntary Class III recall, designated D-0401-2026, for its Gelatin Capsule Pack intended for use with the SODIUM IODIDE I-131 Kit. This critical action, initiated on February 19, 2026, and classified by the FDA on March 20, 2026, directly addresses a significant quality control lapse: the product failed tablet/capsule specifications. The affected product, which includes 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg (manufactured by International Isotopes Inc., Idaho Falls, ID 83401) under NDCs 69208-003-15, 69208-003-25, and 69208-003-35, is distributed nationwide across the United States, including Puerto Rico. For procurement directors and supply chain VPs, this means an immediate disruption in the availability of a crucial ancillary component for a specialized diagnostic and therapeutic agent. The recall encompasses 2,699 blister cartons, specifically from Lot 3666245 (exp: 02/28/2026), Lot 4546213 (exp: 02/28/2026), and Lot 4951280 (exp: 09/30/2027). This incident underscores the imperative for robust quality assurance protocols not only for active pharmaceutical ingredients but also for every component within a drug delivery system, as failures in seemingly minor elements can lead to widespread product unavailability and regulatory scrutiny.
Operational Impact: Radnostix's Idaho Falls Facility and Distribution Network
The recall originates from Radnostix, Inc.'s operations in Idaho Falls, ID, United States, specifically impacting products linked to their facility at 4137 Commerce Cir, Idaho Falls, ID 83401-1205. While the SODIUM IODIDE I-131 drug itself (ANDA209166) is a human prescription drug, the current recall pertains to the associated Gelatin Capsule Pack. This distinction is vital for regulatory affairs heads, as it highlights that quality issues can arise from any part of the manufacturing and packaging process, even for components supplied by third parties like International Isotopes Inc. for the Dibasic Sodium Phosphate Capsules. The nationwide distribution pattern, encompassing the entire U.S. and Puerto Rico, signifies a broad logistical challenge for Radnostix in retrieving the 2,699 affected blister cartons. For business development executives, this event may necessitate a review of supplier qualification processes for all components, particularly those integral to specialized pharmaceutical kits. The Class III classification indicates that while the product is violative, its use is not likely to cause adverse health consequences, yet the operational and reputational costs for Radnostix and potential downstream partners remain significant. The firm initiated this as a voluntary recall, suggesting an internal identification of the issue, which is a positive step in compliance but does not negate the supply disruption.
Supply Chain Vigilance: Implications of Pharmaceutical Component Quality Failures
This Radnostix recall of Gelatin Capsule Packs for the SODIUM IODIDE I-131 Kit serves as a critical reminder for procurement directors and supply chain VPs about the pervasive risks within complex pharmaceutical supply chains. The failure of 'tablet/capsule specifications' for an ancillary component, even if classified as Class III, can still lead to significant operational hurdles and patient care disruptions. For companies relying on such specialized kits, this incident necessitates an immediate audit of their own inventory of Radnostix's affected lots (3666245, 4546213, 4951280) and a reassessment of their qualification processes for all component suppliers. Regulatory affairs heads should note that the FDA's scrutiny extends beyond the active drug substance to the integrity of the entire product presentation. While specific alternative suppliers for this exact capsule pack are not detailed in the available intelligence, the event underscores the need for pre-qualified secondary sources for all critical components, especially for products with nationwide distribution. The absence of a readily available alternative could lead to delays in patient treatment involving SODIUM IODIDE I-131, impacting healthcare providers and ultimately patient outcomes. Proactive risk mitigation, including diversified sourcing strategies and rigorous incoming material inspections, is paramount to safeguard against such unforeseen disruptions.
Broader Regulatory Landscape: Persistent Quality Control Challenges Across the Industry
The Radnostix recall, while specific to its Gelatin Capsule Pack for SODIUM IODIDE I-131, is not an isolated incident within the broader pharmaceutical regulatory landscape. Recent parallel events highlight a persistent pattern of quality control deficiencies across various industry players. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and Spectra Medical Devices encountered similar issues with Lidocaine HCl Injection. Guardian Drug Co. Inc. initiated a nationwide recall for Calcium Carbonate Antacids due to metallic contamination, while Eugia US LLC recalled Lidocaine HCl Injection for labeling deficiencies. These incidents, occurring in close proximity to the Radnostix event, collectively signal an elevated focus by the FDA on manufacturing quality, sterility, and product integrity across diverse pharmaceutical categories. For regulatory affairs heads and business development executives, this trend mandates a proactive review of internal quality management systems, supplier audit programs, and compliance frameworks. The cost of non-compliance, even for Class III issues, extends beyond direct recall expenses to reputational damage and potential market share erosion. Investing in robust quality assurance and control measures is no longer merely a compliance exercise but a strategic imperative to maintain market access and ensure uninterrupted supply.